MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure

OBJECTIVE:A novel, ready-to-use, liquid stable, continuous subcutaneous glucagon infusion (CSGI; Xeris Pharmaceuticals) was evaluated for the treatment of adults with type 1 diabetes (T1D) with documented Hypoglycemia Associated Autonomic Failure (HAAF). METHOD:This was a Phase 2 prospective, multi-...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Endocr Soc
Päätekijät: Pettus, Jeremy H, Nakhle, Samer, Ovalle, Fernando, Rickels, Michael Roehrhoff, Umpierrez, Guillermo Enrique, Junaidi, Khaled, Close, Nicole C, Nguyen, Anh
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Diabetes Mellitus and Glucose Metabolism
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7208249/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.2331
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia